Introduction: Acquired myasthenia gravis (MG) is an autoimmune disease due to anti-acetylcholine receptor antibodies (anti-AChR) that damage nicotinic acetylcholine receptors on neuromuscular junctions. Variable proportions of generalized MG patients were reported to have undetectable serum anti-AchR level, designated as seronegative MG (SNMG) but without clear definitions of SNMG. One group reported that antibodies against muscle-specific kinase was the pathogenetic basis of SNMG. The exact pathogenesis of SNMG is not yet certain and genuine frequency is unknown. Methods: Patients with MG in neurology clinic were studied with clinical, radiological, serological, electrophysiological and histological data reviewed. Patients with initial negative anti-AChR had the assay repeated at least 12 months apart from the first one, together with anti-striational antibody test. Patients with family history of MG had EMG results repeated in details to exclude congenital MG. Patients with repeatedly negative anti-AChR binding assays had serum tested for anti-AChR modulating antibodies (a bioassay using cultured muscel cells) and P/Q type calcium channel antibodies to look for Lambert-Eaton myasthenic syndrome. Only patients with repeatedly negative anti-AchR binding and anti-striational antibodies, negative for anti-AchR modulating and calcium channel antibodies, and with congenital MG excluded were defined as SNMG. Results: A total 52 MG patients were studied, 21 had pure ocular MG and 31 had generalized MG. Three had turned seropositive upon repeated assay and 1 had positive test for modulating antibodies only. One patient with family history of had congenital MG upon detailed EMG. Only 2 of the 31 generalized MG patients (6.5%) were SNMG. One of the 2 generalized SNMG patient had thymic hyperplasia. No SNMG patients had thymoma. SNMG is more common in pure ocular MG patients. Conclusion: Generalized SNMG is rare. Strigent criteria are required for diagnosis of SNMG. Thymic hyperplasia, but not thymoma, can occur in SNMG. We postulate that a subgroup of SNMG patients may have low titer of high affinity anti-AchR undetectable by current assays.
